Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 9/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5350591 | 0.83 | CTSL (0.52) | ACEFKBP1ACTSL | |
| SCHEMBL3885067 | 0.78 | ACE (0.48) | ACE | |
| SCHEMBL18806512 | 0.74 | FKBP1A (0.61) | ACEFKBP1ACYP3A4TSHR | |
| SCHEMBL10343310 | 0.74 | FKBP1A (0.61) | ACEFKBP1ACYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL8040977 | 0.73 | FKBP1A (0.60) | ACEFKBP1ACYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL11217224 | 0.73 | FKBP1A (0.60) | ACEFKBP1ACYP3A4TSHR | |
| SCHEMBL10959623 | 0.71 | ACE (0.52) | ACEFKBP1ACYP3A4 | |
| SCHEMBL9594309 | 0.71 | ACE (0.52) | ACEFKBP1ACYP3A4 | |
| SCHEMBL9698092 | 0.71 | ACE (0.52) | ACEFKBP1ACYP3A4TSHR | |
| SCHEMBL9698089 | 0.71 | ACE (0.52) | ACEFKBP1ACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534896-B2 | Process for the synthesis of perindopril and its pharmaceutically acceptable salts | LES LABORATORIES SERVIER (FR) | 2009-05-19 | — | — | US | disclosed |
| US-7534896-B2 | Process for the synthesis of perindopril and its pharmaceutically acceptable salts | LES LABORATORIES SERVIER (FR) | 2009-05-19 | — | — | US | disclosed |
| US-20070010572-A1 | NOVEL METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF | LES LABORATOIRES SERVIER (FR) | 2007-01-11 | — | — | US | disclosed |
| US-20070010572-A1 | NOVEL METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF | LES LABORATOIRES SERVIER (FR) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010572-A1 | NOVEL METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF | ACE, QDPR, REN | ACE 1/4885FKBP1A 146/4885CTSL 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.